To overcome this drawback, we further purified our AD-Tau preparation via immunoaffinity in a limited set of LTP and fear conditioning experiments confirming our results from preparations obtained without the last immunoaffinity step. The gene discussed is MAPT; the disease is Alzheimer disease.